Can lamotrigine (Lamictal) and levetiracetam (Keppra) cause elevation of liver enzymes?

Can Lamictal and Keppra Cause Elevation in Liver Function Tests?

Yes, both lamotrigine (Lamictal) and levetiracetam (Keppra) can cause liver enzyme elevations, though the risk profiles differ significantly between the two medications.

Levetiracetam (Keppra) and Liver Enzymes

Levetiracetam has minimal hepatotoxic potential and does not typically cause clinically significant liver enzyme elevations. According to the FDA drug label, there were no meaningful changes in mean liver function tests in controlled trials, and LFT abnormalities were similar between drug and placebo groups (1.4%) 1. Only 1 out of approximately 1,400 adult epilepsy patients (0.07%) was discontinued from controlled trials for LFT abnormalities 1.

However, rare but serious cases exist:

• Case reports document liver injury ranging from asymptomatic transaminase elevations to fulminant liver failure 2, 3, 4
• When liver injury occurs, it typically presents within 3-120 days (median 19 days) of initiation 2
• Clinical manifestations include fever, digestive symptoms, and rash in 76% of cases, though 24% remain asymptomatic with only elevated enzymes 2
• Most cases resolve within 2-270 days (median 9 days) after discontinuation 2

The key clinical point: Keppra-induced liver injury is rare but can be severe when it occurs, and routine LFT monitoring is not required by FDA labeling.

Lamotrigine (Lamictal) and Liver Enzymes

Lamotrigine carries a more significant risk of liver enzyme elevation, particularly as part of multiorgan hypersensitivity reactions. The FDA drug label explicitly warns about multiorgan hypersensitivity reactions (DRESS) that can present with hepatitis, and isolated liver failure without rash has been reported 5.

Key risk factors and patterns:

• Atypical antipsychotics (a drug class that includes similar mechanisms) may produce transient hepatic transaminase elevations 6
• Lamotrigine-associated liver injury can range from mild transaminase elevations to fatal hepatic failure 7, 8
• Cases have documented AST up to 6,079 IU/L and ALT up to 6,900 IU/L 8
• Liver injury typically occurs within 2-3 weeks of initiation 7, 8
• Concomitant valproate increases the risk of serious reactions in both adults (1% vs 0.16%) and children (1.2% vs 0.6%) 5

Clinical Monitoring Recommendations

For Levetiracetam:

• Baseline LFTs are not required by FDA labeling
• Monitor clinically for symptoms (jaundice, right upper quadrant pain, nausea, fatigue)
• Consider checking LFTs if symptoms develop or in patients on long-term therapy 2
• No routine monitoring schedule is established

For Lamotrigine:

• Obtain baseline liver function tests before initiating treatment 6
• Monitor periodically during ongoing therapy, particularly in the first 18 months 6
• Increase monitoring frequency if patient develops fever, rash, or systemic symptoms 5
• Immediately discontinue if signs of hypersensitivity develop (fever, rash, lymphadenopathy) even without LFT elevation 5

Common Pitfalls to Avoid

1. Don't assume Keppra is completely hepatically inert - while rare, severe liver injury can occur 3, 4
2. Don't miss early hypersensitivity signs with Lamictal - fever and lymphadenopathy may precede rash or LFT elevation 5
3. Don't continue either medication if unexplained LFT elevation occurs - discontinuation is the primary treatment 8, 2
4. Don't overlook drug interactions - enzyme-inducing AEDs affect both medications differently 9, 1

When to Discontinue

Stop immediately if:

• AST/ALT >3× upper limit of normal with symptoms
• Any signs of multiorgan involvement (fever, rash, eosinophilia, lymphadenopathy)
• Progressive elevation despite initial observation
• Development of jaundice or coagulopathy

Both medications should be permanently discontinued if drug-induced liver injury is confirmed, as rechallenge carries significant risk of more severe reaction 5, 8, 4.